Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
An RX mirror and its underlying label are not independent clinical confirmations.
Check source scope before reading a dose
ZYNYZ: selected renal PK and nephritis mirror passages
Product / population
Adult IV ZYNYZ for labeled oncology indications. Baseline pharmacokinetics and immune-mediated nephritis management are different questions.
GlobalRPh RX List / label mirror · Adult IV ZYNYZ for labeled oncology indications. Baseline pharmacokinetics and immune-mediated nephritis management are different questions.
Renal method: eGFR >=26 mL/min/1.73 m2; CTCAE creatinine grading Source date: Not established in reviewed passage Retrieved: 2026-11-07
Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Pharmacokinetic observation only. A drug-exposure observation is not itself a dose recommendation.
Before using this finding
Confirm product, indication, renal measure and dialysis modality before applying.
Dialysis evidence: No dialysis regimen established in selected content
Selected named sections summarized; not a complete monograph or independent clinician approval.
Selected renal sections
The selected mirror describes the eGFR 26 mL/min/1.73 m2 lower studied boundary and nephritis-related withholding for grade 2/3 creatinine increases, with permanent discontinuation for grade 4. Read full resumption and steroid-taper requirements in the official label.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh Renal Dosing Master v7.4. Review the retrieval and revision dates attached to each source. Selecting a reference does not imply clinical verification.
